# Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis

> **NCT07146087** · EARLY_PHASE1 · SUSPENDED · sponsor: **Biocells Medical** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** MSC-Derived Exosomes
- **BIOLOGICAL:** Placebo (Normal Saline)

## Key facts

- **NCT ID:** NCT07146087
- **Lead sponsor:** Biocells Medical
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-07-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Slow enrolment of participants
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146087, "Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07146087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*